CSIMarket Company Name, Ticker, Suppliers, else..
 
Renovaro Inc   (NASDAQ: RENB)
Other Ticker:  
 
 
Price: $0.3527 $0.01 4.257%
Day's High: $0.3383 Week Perf: -5.39 %
Day's Low: $ 0.30 30 Day Perf: -39.06 %
Volume (M): 157 52 Wk High: $ 2.34
Volume (M$): $ 48 52 Wk Avg: $0.89
Open: $0.34 52 Wk Low: $0.30



 Market Capitalization (Millions $) 57
 Shares Outstanding (Millions) 162
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -126
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Renovaro Inc
Renovaro Biosciences Inc is a biotechnology company that focuses on developing innovative therapies for serious medical conditions. The company is dedicated to the research, development, and commercialization of various medical treatments and diagnostic tools. Renovaro Biosciences Inc aims to bring breakthrough therapies to patients, addressing a wide range of diseases including cancer, autoimmune disorders, and genetic disorders. Their mission is to improve patients' lives through the advancement of cutting-edge biotechnologies and precision medicine.


   Company Address: 2080 Century Park East  Los Angeles 90067 CA
   Company Phone Number: 918-1980   Stock Exchange / Ticker: NASDAQ RENB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY        3.03% 
PBYI        0.33% 
REGN   -2.35%    
SPRO   -11.72%    
TEVA        9.03% 
VTRS        6.79% 
• View Complete Report
   



Management Announcement

Renovaro Inc. Seals Milestone Payment with Predictive Oncology Amidst Transformative Merger with BioSymetrics as Stock Price Sees Moderate Uplift,

Published Mon, Mar 3 2025 2:15 PM UTC

Renovaro Inc. Advances as It Finalizes Agreement with Predictive Oncology Amidst Strategic Moves in BiotechnologyIn a notable advancement for Renovaro Inc. (NASDAQ: RENB), the biotechnology company has successfully completed its first milestone payment to formalize a definitive agreement with Predictive Oncology. This move signifies a pivotal step toward forging a relationsh...
Merger and Acquisition

Renovaro and BioSymetrics Join Forces in Landmark Merger to Revolutionize AI-Driven Biomarker Discovery and Precision Medicine

Published Wed, Feb 26 2025 6:25 PM UTC

Breaking News: Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision MedicineIn a significant development for the biotechnology sector, Renovaro Inc. (NASDAQ: RENB) has announced a definitive merger agreement with BioSymetrics, a leader in artificial intelligence-driven healthcare solutions. The merger, which ai...
Partnership

Renovaro and Nebul Forge Strategic Alliance to Transform Early Disease Detection via AI-Driven Innovations,

Published Fri, Dec 20 2024 2:00 PM UTC

Renovaro and Nebul Join Forces to Propel Early Disease Detection Through Strategic Collaboration In an era where early disease detection can significantly enhance treatment outcomes and improve patient quality of life, Renovaro, a pioneering biotechnology company, has announced a strategic collaboration with Nebul, a leading innovator in health technology. This partnership a...
Partnership

Alliance of Progress PersonalAIze and Cube Forge Unite for AI-Driven Medical Innovation Amidst Sector Challenges,

Published Thu, Sep 19 2024 1:00 PM UTC

CSIMarket.com A Groundbreaking Alliance: PersonalAIze and Cube Forge Transformative Partnership to Propel AI in Healthcare In an age wherein the delicate flowers of progress burgeon, the partnership between PersonalAIze and Cube Forge emerges as a cataclysmic force aimed at the rapid advancement of AI-driven healthcare solutions. This significant collaboration aspires to ...
Product Service News

RenovaroCube to Advance Cancer Diagnostics with Advanced Multi-Omics Research at ESMO 2024,

Published Fri, Sep 13 2024 1:00 PM UTC

RenovaroCube (NASDAQ: RENB), a trailblazer in AI-driven innovations harnessing multi-omics technology for cancer profiling, is set to unveil its groundbreaking research at the esteemed European Society for Medical Oncology (ESMO) Congress in Amsterdam on September 15, 2024. The company will present two pivotal scientific studies that underscore its commitment to transforming...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com